Recent advances in the treatment of drug resistant tuberculosis

Multidrug-resistant (MDR TB) tuberculosis (TB), resistant to isoniazid and rifampicin, continues to be one of the most important threats to controlling the TB epidemic. Over the last few years, there have been promising advances in the paradigm of MDR TB treatment: new drugs have shown activity against Mycobacterium tuberculosis (MBT) and several all-oral short regimens to treat MDR TB have shown promising results. The purpose of this comprehensive review is to summarize the recommended regimens to treat MDR TB, and we also summarize new insights into the treatment of patients with MDR TB.